Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I second ATL. Good point! These so called fair reviewers are not able to come up with a better treatment regime or trial to-date and they shadow or pretend they do not know our PCLYC trial where DcVaxL has been independently tested which masks all the naysayers' resistances. And the second combo bomb with CI Keytruda is really an undeniable evidence that DcVaxL is indispensable in the oncology space soon. The wise people in the space are watching. Yes, tip of the ice berg. LP has several supporting data to go with the application, imo.
Agreed. They did not want to talk about the actual OS tail for both nGBM and rGBM. The tail of the rGBM clearly demonstrates the concept of using the resected tumor even the original one yields benefits; imagine the repeat ones.
I am NOT voting this time. Enough got fooled last time. But if I don't vote, by default does it go to the Denner gang??
Interesting! Thanks flipper for sharing.
ok 77 then
Not a threat. Yet to see, how to treat once progressed. DCVaxL MOA explained in slide 16 in the presentation by Dr. B is the best approach to treat any solid cancer. Like Gary suggested, combo with DCVaxL would help the ones whose tumor reached progression taking Servier’s drug. Often and often DCVaxL stands out among all the competitors for years after years. Isn’t it amazing! Again the merit goes to Slide 16.
Gary, God bless you brother, your IMGn is up in the pre-market again. Thanks to you I bought some call options.
https://finance.yahoo.com/quote/IMGN?p=IMGN&.tsrc=fin-srch
Dan et al., Dr. Bosch did NOT share the PCLYC or Keytruda combo results yesterday but told DCVaxL is good for combos.
Hmmm so will MRK say something tomorrow after hrs? Yet to see.
So you are betting on the financials but beatrap says the.Company has loyal supporters. Do you think they are going to let it happen what you want to happen? Sorry for you. Bigger says Water flows where it wants to.
Roman, look at the discussion on Platform buying in the Oncology and immunology and cancer vaccine therapy space.
https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/?refcode=TechReport-06022023-2-FA-1:06:2023:2Q:NewsLetter:Email:TechReport-06022023:na:na:na:na:02:13:2:FA:1&j=2273842&sfmc_sub=103639478&l=222_HTML&u=31949780&mid=100016628&jb=9004
Shorts are losing their shirts now. They are still fighting hard. They are going to lose everything pretty soon. China is a big deal. Buyout is coming now all on a sudden, imo.
China approval is huge! I always believe in Justice. Finally God has opened his eyes for the Amarin Longs; hopefully we go back to double digits soon irrespective of the approval is for triglycerides.
Is it a fact they are opening up sales positions in the USA?? these positions are real??Can someone confirm??if yes, I like to load shares now.
Link the JAMA article into her Linkedin message.
Please post it in her LinkedIn account.
https://www.linkedin.com/in/arati-prabhakar-a366737/
Our Baxter should send his NWBO synopsis to Dr. Prabhakar as she is asking for ideas anyway. TDD, ATL, BB, Senti, flipper, docloguc, biosect, kabu and who else not could write to Dr. P too. Asap please.
Keep plucking your hairs.
I second. Thanks biosect for explaining the uniqueness of DCVaxL. Yes, we see DCVaxL is the best personalized, in fact fully personalized, both in terms of tumor proteins and immune cells …immunotherapy vaccine compared to mRNA or Provenge or the CIs for that matter.
Thanks Lykiri for checking with LL. ATL the Great, thanks for all you do; you are the Wikipedia of NWBO. LL said it. Now flipper, Lykiri and everyone is agreeing with you A great piece of discovery by all of your team work. Kudos to all of you! If the median is not reached yet, does it have to run till it is reached? Can it not be halted for overwhelming efficacy??
Good Legwork! Thanks for the extra mile you are travelling in educating us.
Now we are clear that the future DcVaxL drug includes PCLYC, and those interferons.
Move the price up
watch. 82k is nothing. But I taught them to have a buffer all the time. Well trained now. Ok even if you dump on us at the end of the day. Green pasture is everywhere in the NWBO land now.
Fasten your seat belts!!!!!!!!!
We will probably know who gave that $3M at ASCO, imo.
Interesting to note that the regulators either are already seeing the Trial Master File or about to see it. Go NWBO!
Management has told enough in the 10Q. $3M prepayment.... I am sure my new minions are happy loading cheap shares. Of course, my patriotic long ones too!
Is there a spin in the ECA acceptance by the MHRA??
No, Power Hr will be interesting.
Good point Reefrad. Yes ref 95 is the 2018 JTM paper and 126 is the 2022 NYAS conf citation. Yep seems JAMA article was not available to these authors, had it been, would have changed their last sentence.
Thanks for sharing such a great article. These Type 1 Type 2 errors are bundled into but grossly ignored requiring a P value of 0.005 blindly and stupidly by the mighty FDA in their approval process irrespective of the outcome of the trials on hard to treat cancers like GBM and pancreatic. Good thing is our DCVaxL trial still meets this P value in its mOS endpoint even though median metric in immunotherapy trials is too harsh because median reach too fast too early in immunotherapy while the tail drags for too long. In other words, immunotherapy trials should be evaluated based on the long tail of percentage survival Vs. length of survival. Another good thing is whichever way the RAs dissect it, DCVaxL phase 3 trial is a huge success, imo. This is because the therapy works.
And after seeing all these outcome out of those open arm combo trials, no wonder Merck did NOT buy SGEN for $40B.
Yep Locknload56, there were about 350 people attended the event celebrating 75 yrs of life of a great philanthropist and bio device company entrepreneur. You know Escondido and Carlsbad are full of bio CEOs and real estate developers and Tesla early retirees and Google/FB lawyers and Roche/BMY marketing managers, and IT and SpaceX project leads. Almost everyone is aware of NWBO and are diligently making their moves. I am planning to attend the November SITC meeting in San Diego. Hope to see you soon. Let us party!
And I have given classes to my minions not to deplete their buying power rushing to buy all at once. Play by the tunes of the shorts is the mantra they were taught, meaning wait but act before they scoop out all the stop loss limit orders.
I recruited new minions this weekend and are buying this whole week.
Wow Locknload56, good to know you are an Escondido resident. I am visiting my cousin who lives here over 15+ yrs.
I will be hanging around here at the Centre at Lexus tomorrow.
If you have time stop by. Thanks!
SATURDAY, MAY 6TH 2023
11.30AM - 2.30PM
THE CENTRE AT LEXUS
1205 AUTO PARK WAY
ESCONDIDO. C1 92029
wow only about 30 miles from Escondido where the party is. While I return back to the SAN airport tomorrow, I will drive thru La Jolla. Thanks for the tips Horseb4CarT.
yes Sojo, we are like you, a long long longs. We breathe NWBO in and out. We are supporting the Company in as many ways as possible as they work hard diligently reaching the finish line. It is happening!!!!!!!!!!
Sojo, I am on my way to San Diego attending an event tomorrow, a large community gathering. There are some newbies from that group buying today; they are lucky they get cheap shares. I am absolutely happy for them.
Judge/Sojo, news is coming next week, imo.
Themo says the management has access to funds. It means no dilution but it means what it means. Thermo and Biggers are going to make sure Les got all the money he needs to take us to the finish line. Now Ex paupers will now make a mountain out in the vacuum.